HERON THERAPEUTICS, INC. /DE/ (HRTX) Gross margin 2016–2025
HERON THERAPEUTICS, INC. /DE/ (HRTX) gross margin by fiscal year — reported gross profit divided by reported revenue.
73.3%FY2025 · since FY2016: 97.3% → 73.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 73.3% | +0.1 pp |
| FY2024 | 73.2% | +24.5 pp |
| FY2023 | 48.8% | -0.3 pp |
| FY2022 | 49.0% | +2.3 pp |
| FY2021 | 46.7% | -12.5 pp |
| FY2020 | 59.2% | +1.4 pp |
| FY2019 | 57.8% | -6.7 pp |
| FY2018 | 64.5% | -20.6 pp |
| FY2017 | 85.1% | -12.2 pp |
| FY2016 | 97.3% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More HRTX financial trends
HRTX RevenueHRTX Net incomeHRTX Net marginHRTX Gross profitHRTX Operating incomeHRTX Operating marginHRTX Operating cash flowHRTX Free cash flowHRTX Capital expendituresHRTX Return on equityHRTX Stock buybacksHRTX Dividends paidHRTX Total assetsHRTX Total liabilitiesHRTX Shareholders’ equityHRTX overview →